NCT03571191View on ClinicalTrials.gov

Denosumab Treatment for Fibrous Dysplasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

November 17, 2021

Study Completion Date

March 15, 2030

Conditions
Bone DiseasesPain
Interventions
DRUG

Denosumab

Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Dental and Craniofacial Research (NIDCR)

NIH